BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 24082082)

  • 1. A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2.
    Tremblay JM; Mukherjee J; Leysath CE; Debatis M; Ofori K; Baldwin K; Boucher C; Peters R; Beamer G; Sheoran A; Bedenice D; Tzipori S; Shoemaker CB
    Infect Immun; 2013 Dec; 81(12):4592-603. PubMed ID: 24082082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenovirus vector expressing Stx1/Stx2-neutralizing agent protects piglets infected with Escherichia coli O157:H7 against fatal systemic intoxication.
    Sheoran AS; Dmitriev IP; Kashentseva EA; Cohen O; Mukherjee J; Debatis M; Shearer J; Tremblay JM; Beamer G; Curiel DT; Shoemaker CB; Tzipori S
    Infect Immun; 2015 Jan; 83(1):286-91. PubMed ID: 25368111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Evaluation of a Novel VHH-Based Immunocapture Assay for High-Sensitivity Detection of Shiga Toxin Type 2 (Stx2) in Stool Samples.
    Melli LJ; Zylberman V; Hiriart Y; Lauche CE; Baschkier A; Pardo R; Miliwebsky E; Chinen I; Rivas M; Goldbaum FA; Ugalde JE; Comerci DJ; Ciocchini AE
    J Clin Microbiol; 2020 Feb; 58(3):. PubMed ID: 31826960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shiga toxin 2-specific but not shiga toxin 1-specific human monoclonal antibody protects piglets challenged with enterohemorrhagic Escherichia coli producing shiga toxin 1 and shiga toxin 2.
    Jeong KI; Tzipori S; Sheoran AS
    J Infect Dis; 2010 Apr; 201(7):1081-3. PubMed ID: 20196656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Deleterious Effects of Shiga Toxin Type 2 Are Neutralized In Vitro by FabF8:Stx2 Recombinant Monoclonal Antibody.
    Luz D; Gómez FD; Ferreira RL; Melo BS; Guth BEC; Quintilio W; Moro AM; Presta A; Sacerdoti F; Ibarra C; Chen G; Sidhu SS; Amaral MM; Piazza RMF
    Toxins (Basel); 2021 Nov; 13(11):. PubMed ID: 34822608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New high-affinity monoclonal antibodies against Shiga toxin 1 facilitate the detection of hybrid Stx1/Stx2 in vivo.
    Skinner C; Patfield S; Stanker LH; Fratamico P; He X
    PLoS One; 2014; 9(6):e99854. PubMed ID: 24914553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shiga toxin-producing Escherichia coli infection and antibodies against Stx2 and Stx1 in household contacts of children with enteropathic hemolytic-uremic syndrome.
    Ludwig K; Sarkim V; Bitzan M; Karmali MA; Bobrowski C; Ruder H; Laufs R; Sobottka I; Petric M; Karch H; Müller-Wiefel DE
    J Clin Microbiol; 2002 May; 40(5):1773-82. PubMed ID: 11980959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction between Shiga toxin and monoclonal antibodies: binding characteristics and in vitro neutralizing abilities.
    Rocha LB; Luz DE; Moraes CT; Caravelli A; Fernandes I; Guth BE; Horton DS; Piazza RM
    Toxins (Basel); 2012 Sep; 4(9):729-47. PubMed ID: 23105978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of camelid single chain antibodies against Shiga toxin type 2 (Stx2) with therapeutic potential against Hemolytic Uremic Syndrome (HUS).
    Mejías MP; Hiriart Y; Lauché C; Fernández-Brando RJ; Pardo R; Bruballa A; Ramos MV; Goldbaum FA; Palermo MS; Zylberman V
    Sci Rep; 2016 Apr; 6():24913. PubMed ID: 27118524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Poly-N-acetylglucosamine-Shiga toxin broad-spectrum conjugate vaccine for Shiga toxin-producing Escherichia coli.
    Lu X; Skurnik D; Pozzi C; Roux D; Cywes-Bentley C; Ritchie JM; Munera D; Gening ML; Tsvetkov YE; Nifantiev NE; Waldor MK; Pier GB
    mBio; 2014 Mar; 5(2):e00974-14. PubMed ID: 24667709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody response to Shiga toxins Stx2 and Stx1 in children with enteropathic hemolytic-uremic syndrome.
    Ludwig K; Karmali MA; Sarkim V; Bobrowski C; Petric M; Karch H; Müller-Wiefel DE;
    J Clin Microbiol; 2001 Jun; 39(6):2272-9. PubMed ID: 11376069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2.
    Smith MJ; Teel LD; Carvalho HM; Melton-Celsa AR; O'Brien AD
    Vaccine; 2006 May; 24(19):4122-9. PubMed ID: 16551486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective efficacy and pharmacokinetics of human/mouse chimeric anti-Stx1 and anti-Stx2 antibodies in mice.
    Melton-Celsa AR; Carvalho HM; Thuning-Roberson C; O'Brien AD
    Clin Vaccine Immunol; 2015 Apr; 22(4):448-55. PubMed ID: 25716230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and characterization of monoclonal antibodies against Shiga toxin 2 and their application for toxin detection in milk.
    He X; McMahon S; Skinner C; Merrill P; Scotcher MC; Stanker LH
    J Immunol Methods; 2013 Mar; 389(1-2):18-28. PubMed ID: 23279946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic toxoids of Shiga toxin types 1 and 2 protect mice against homologous but not heterologous toxin challenge.
    Wen SX; Teel LD; Judge NA; O'Brien AD
    Vaccine; 2006 Feb; 24(8):1142-8. PubMed ID: 16198455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and characterization of recombinant antibody fragments that recognize and neutralize in vitro Stx2 toxin from Shiga toxin-producing Escherichia coli.
    Luz D; Chen G; Maranhão AQ; Rocha LB; Sidhu S; Piazza RM
    PLoS One; 2015; 10(3):e0120481. PubMed ID: 25790467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Shigatoxin 1 protective for the development of Shigatoxin 2-related hemolytic uremic syndrome in children? Data from the ItalKid-HUS Network.
    Ardissino G; Possenti I; Vignati C; Daprai L; Capone V; Brigotti M; Luini MV; Consonni D; Montini G
    Pediatr Nephrol; 2020 Oct; 35(10):1997-2001. PubMed ID: 32734345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of TLR4 as the receptor that recognizes Shiga toxins in human neutrophils.
    Brigotti M; Carnicelli D; Arfilli V; Tamassia N; Borsetti F; Fabbri E; Tazzari PL; Ricci F; Pagliaro P; Spisni E; Cassatella MA
    J Immunol; 2013 Nov; 191(9):4748-58. PubMed ID: 24068665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of a product anti-Shiga toxin for prevention of the hemolytic uremic syndrome].
    Hiriart Y; Pardo R; Bukata L; Lauché C; Muñoz L; Colonna M; Goldbaum F; Sanguineti S; Zylberman V
    Medicina (B Aires); 2018; 78(2):107-112. PubMed ID: 29659360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bimodal Response to Shiga Toxin 2 Subtypes Results from Relatively Weak Binding to the Target Cell.
    Cherubin P; Fidler D; Quiñones B; Teter K
    Infect Immun; 2019 Dec; 87(12):. PubMed ID: 31527121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.